NEWS RELEASE
Jun 18, 2007 09:44 ET
WINNIPEG, MANITOBA--(Marketwire - June 18, 2007) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce an independent research publication on the Company's DispersinB technology, a patent pending anti-biofilm technology. The paper appeared in the recent edition of online scientific journal 'Antimicrobial Agents and Chemotherapy' published by American Society for Microbiology.
The research findings reported in the publication, entitled "Synergistic activity of dispersin B and cefamandole nafate in the inhibition of staphylococcal growth on polyurethanes" co-authored by Dr. Gianfranco Donelli from the Department of Health, Istituto Superiore di Santa, Rome, Italy, and Dr. Jeff Kaplan from the Department of Oral Microbiology, the University of Medicine and Dentistry of New Jersey (UMDNJ), demonstrates that DispersinB is not cytotoxic and that DispersinB treatment makes bacteria growing in biofilms more susceptible to an antibiotic such as cefamandole nafate.
"This research not only provides evidence that the DispersinB enzyme is non-toxic but also demonstrates that when DispersinB is combined with an antibiotic it enhances the activity of the antibiotic against biofilm-embedded bacteria such as Staphylococcus epidermidis" stated Dr. Kaplan, also the inventor of the technology. "These findings confirm that DispersinB-antibiotic combinations provide highly effective tools for preventing bacterial colonization of medical devices, including catheters."
"This study provides solid evidence that our technology is very effective in the fight against biofilms that attach to medical devices and also demonstrates that naturally occurring DispersinB is not cytotoxic." said Gord Froehlich, President and CEO of Kane Biotech. "Our database of scientific evidence continues to grow as we prepare this technology for commercialization."
DispersinB is a novel enzyme capable of both inhibiting and dispersing bacterial biofilms. Kane Biotech has a worldwide exclusive license to all human, animal and industrial applications of DispersinB from the UMDNJ. Kane Biotech is presently using dispersinB alone, and in combination with other antimicrobial agents to develop a proprietary medical device coating.
About Dr. Jeffrey Kaplan
Jeffrey Kaplan received a Bachelor of Science degree in Biology from the University of Illinois at Chicago in 1980 and a Ph.D. in Molecular Biology from the same institution in 1985. He received postdoctoral training in the Department of Microbiology at the Albert Einstein College of Medicine, Bronx, N.Y., and in the Department of Microbiology at Columbia University, College of Physicians and Surgeons, New York, N.Y. Dr. Kaplan worked for 10 years in the Oncology Department at Wyeth Pharmaceuticals, Pearl River, N.Y., before joining the Department of Oral Biology at New Jersey Dental School in 1999.
Dr. Kaplan's lab is studying the detachment and dispersal of bacterial cells from biofilms with an emphasis on the gram-negative periodontal pathogen Aggregatibacter actinomycetemcomitans. His research is funded by the several grant agencies, including the National Institute of Health (NIH), USA. His discovery of DispersinB supported by the NIH grant was listed in the "NIH Annual Performance Report of 2004" as one of the thirteen achievements of the year.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse microbial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech Inc. uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has a great potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact
Kane Biotech Inc.
Justin Gagnon
Investor Relations Professional
(204) 478-5602
(204) 453-1314 (FAX)
Email: jgagnon@kanebiotech.com
Website: www.kanebiotech.com
Showing posts with label Press Release. Show all posts
Showing posts with label Press Release. Show all posts
Tuesday, June 19, 2007
Saturday, June 9, 2007
NEWS RELEASE-FDA Science Board to Meet on June 14
News Release
FOR IMMEDIATE RELEASE
P07-100
June 8, 2007
Media Inquiries:
301-827-6242
Consumer Inquiries:
888-INFO-FDA
The U.S. Food and Drug Administration's (FDA) Science Board will hold a public meeting on June 14, 2007. The board, an advisory committee to the FDA, provides the agency with expert outside advice on specific technical issues, as well as emerging issues within the scientific community, industry, and academia. Members counsel the agency on regulatory science, the formulation of an appropriate research agenda, and on upgrading FDA's scientific and research facilities.
"Science provides the foundation for FDA's regulatory decisions," said Janet Woodcock, M.D., FDA's deputy commissioner and chief medical officer. "Science and technology are creating products with enormous promise and, frequently, considerable challenges. This in-depth review of our scientific capacity is critical to assuring that FDA will continue to meet the regulatory challenges of the future."
Members of the board will address food protection, the agency's interim safety/risk assessment of melamine, a report on the Antimicrobial Resistance Monitoring System (NARMS), and an agency-wide review of FDA science. For a complete agenda, briefing documents, and a list of subject matters experts that serve as advisors to the subcommittee and their affiliations, please see: www.fda.gov/ohrms/dockets/ac/oc07.htm#ScienceBoard.
The board, chaired by Kenneth Shine, M.D., University of Texas System, Austin, is composed of nine members. Other members include: Gail H. Cassell, Ph.D., Eli Lilly and Company, Indianapolis; Susan Kay Harlander, Ph.D., BT Safety, LLC, Eden Prairie; Lonnie King, D.V.M., Centers for Disease Control and Prevention, Atlanta; Barbara J. McNeil, M.D., Ph.D., Harvard Medical School, Boston; David R. Parkinson, M.D., Biogen Idec, San Diego, Calif.; F. Xavier Pi-Sunyer, M.D., St. Luke's-Roosevelt Hospital Center, New York; Allen D. Roses, M.D., GlaxoSmithKline, Research Triangle Park, N.C.; and Larry D. Sasich, Pharm.D., consumer representative, Erie, Pa.
Last year, the board established the Subcommittee for the Review of FDA Science to determine whether the FDA's current science portfolio is properly positioned to deal new regulatory challenges stemming from developments in science and technology.
During the daylong meeting, the Subcommittee will provide an update on the progress of their review. The subcommittee, chaired by Gail H. Cassell, Ph.D., of Eli Lilly and Company, will submit a draft written report of its preliminary findings to the board this summer. The subcommittee has asked 28 scientific subject-matter experts, drawn from government, industry and academia, to contribute to the report.
The Science Board meeting is scheduled for June 14 from 8 a.m. to 4:30 p.m. at the Holiday Inn, 2 Montgomery Village Ave., Gaithersburg, Md.
Public comments can be submitted; please see the Federal Register notice for this meeting for more information: www.fda.gov/OHRMS/DOCKETS/98fr/E7-9737.htm.
####
FOR IMMEDIATE RELEASE
P07-100
June 8, 2007
Media Inquiries:
301-827-6242
Consumer Inquiries:
888-INFO-FDA
The U.S. Food and Drug Administration's (FDA) Science Board will hold a public meeting on June 14, 2007. The board, an advisory committee to the FDA, provides the agency with expert outside advice on specific technical issues, as well as emerging issues within the scientific community, industry, and academia. Members counsel the agency on regulatory science, the formulation of an appropriate research agenda, and on upgrading FDA's scientific and research facilities.
"Science provides the foundation for FDA's regulatory decisions," said Janet Woodcock, M.D., FDA's deputy commissioner and chief medical officer. "Science and technology are creating products with enormous promise and, frequently, considerable challenges. This in-depth review of our scientific capacity is critical to assuring that FDA will continue to meet the regulatory challenges of the future."
Members of the board will address food protection, the agency's interim safety/risk assessment of melamine, a report on the Antimicrobial Resistance Monitoring System (NARMS), and an agency-wide review of FDA science. For a complete agenda, briefing documents, and a list of subject matters experts that serve as advisors to the subcommittee and their affiliations, please see: www.fda.gov/ohrms/dockets/ac/oc07.htm#ScienceBoard.
The board, chaired by Kenneth Shine, M.D., University of Texas System, Austin, is composed of nine members. Other members include: Gail H. Cassell, Ph.D., Eli Lilly and Company, Indianapolis; Susan Kay Harlander, Ph.D., BT Safety, LLC, Eden Prairie; Lonnie King, D.V.M., Centers for Disease Control and Prevention, Atlanta; Barbara J. McNeil, M.D., Ph.D., Harvard Medical School, Boston; David R. Parkinson, M.D., Biogen Idec, San Diego, Calif.; F. Xavier Pi-Sunyer, M.D., St. Luke's-Roosevelt Hospital Center, New York; Allen D. Roses, M.D., GlaxoSmithKline, Research Triangle Park, N.C.; and Larry D. Sasich, Pharm.D., consumer representative, Erie, Pa.
Last year, the board established the Subcommittee for the Review of FDA Science to determine whether the FDA's current science portfolio is properly positioned to deal new regulatory challenges stemming from developments in science and technology.
During the daylong meeting, the Subcommittee will provide an update on the progress of their review. The subcommittee, chaired by Gail H. Cassell, Ph.D., of Eli Lilly and Company, will submit a draft written report of its preliminary findings to the board this summer. The subcommittee has asked 28 scientific subject-matter experts, drawn from government, industry and academia, to contribute to the report.
The Science Board meeting is scheduled for June 14 from 8 a.m. to 4:30 p.m. at the Holiday Inn, 2 Montgomery Village Ave., Gaithersburg, Md.
Public comments can be submitted; please see the Federal Register notice for this meeting for more information: www.fda.gov/OHRMS/DOCKETS/98fr/E7-9737.htm.
####
Thursday, June 7, 2007
Interest in Breakthrough Antimicrobial Technology for Medical Devices Results in Growth for AcryMed
Abstract:
Strong industry interest in SilvaGard, a breakthrough antimicrobial nanotechnology, has resulted in significant growth for AcryMed, the company that developed and now licenses the technology. Built on years of research in developing silver antimicrobial wound treatments, SilvaGard addresses a still un-met clinical need, preventing the spread of deadly medical device-related infections. By harnessing the advantages of nanotechnology with the broad-spectrum infection-fighting ability of Ionic silver, SilvaGard provides a safe and effective solution to render medical devices impervious to infection causing biofilms.
Press Release
Interest in Breakthrough Antimicrobial Technology for Medical Devices Results in Growth for AcryMed
Portland, OR | Posted on June 5th, 2007
To accommodate the increased demand for its patented technologies, AcryMed has recently doubled the size of its laboratory facilities and hired new scientific and technical staff. According to AcryMed, the company has received inquiries that span a large number of medical device markets.
"The spread of hospital acquired infections is a significant problem that unnecessarily effect millions of U.S. patients each year and adds more than 28 billion dollars to our nation's healthcare costs," said Jack McMaken, president of AcryMed. "Since a large portion of harmful bacteria is harbored on medical devices such as indwelling catheters and implants, manufacturers are extremely interested in finding ways to curtail the role their products play in spreading infections. SilvaGard represents the first significant breakthrough in this area in quite some time."
SilvaGard prevents the spread of device-related infections by depositing antimicrobial silver nanoparticles onto the surfaces of medical devices and thus providing a protective barrier. Studies have shown that SilvaGard is not only safe for use, but also highly effective against a wide spectrum of infection-causing bacteria including MRSA and other antibiotic-resistant "superbugs."
The initial FDA market clearance of SilvaGard antimicrobial technology was given to I-Flow Corporation for marketing the company's ON-Q® SilverSoaker™ regional anesthesia delivery catheters. In recent findings presented at the Surgical Infection Society (SIS) meeting, I-Flow's ON-Q SilverSoaker antimicrobial catheter demonstrated a significantly lower risk of developing a surgical site infection in an on-going prospective study of patients undergoing colorectal surgery. The preliminary results captured the outcomes of 120 patients, randomized to either treatment with continuous local anesthetic using the antimicrobial treated ON-Q catheter or to the control treatment employing traditional pain relief. At 30-days post surgery, patients who received treatment with the antimicrobial ON-Q device had a significantly lower incidence of site infections at 0%, as compared to the control group at 22.9%. The study is scheduled to be complete by year-end. To learn more about the benefits of the ON-Q, visit www.AskYourSurgeon.com or www.IFLO.com.
Through collaborative development efforts, AcryMed and its medical device company partners expect to announce new product applications, leveraging SilvaGard-technology in the coming months.
####
About AcryMed
cryMed is a pioneering innovator at the forefront of innovations in the fields of infection control and wound healing. The company's SilvaSorb® products for advanced wound care and SilvaGard nanoparticle surface treatment for medical devices are among the breakthrough technologies that have distinguished AcryMed as an industry leader. AcryMed maintains on-site GMP manufacturing and lab facilities at its Portland, Oregon-based headquarters. The company is ISO certified and operates under ISO 13485 and EN 93/42/EEC. For more information on AcryMed, SilvaSorb, SilvaGard or other wound care and infection control technologies developed by AcryMed, visit their web site at http://www.acrymed.com or call 503-624-9830.
For more information, please click here
Contacts:
Kim Jacque
9560 SW Nimbus Ave.
Beaverton, Oregon 97008
Phone Number: 503.624.9830
Fax Number: 503.639.0846
kjacque@acrymed.com
Copyright © PRWeb™
Strong industry interest in SilvaGard, a breakthrough antimicrobial nanotechnology, has resulted in significant growth for AcryMed, the company that developed and now licenses the technology. Built on years of research in developing silver antimicrobial wound treatments, SilvaGard addresses a still un-met clinical need, preventing the spread of deadly medical device-related infections. By harnessing the advantages of nanotechnology with the broad-spectrum infection-fighting ability of Ionic silver, SilvaGard provides a safe and effective solution to render medical devices impervious to infection causing biofilms.
Press Release
Interest in Breakthrough Antimicrobial Technology for Medical Devices Results in Growth for AcryMed
Portland, OR | Posted on June 5th, 2007
To accommodate the increased demand for its patented technologies, AcryMed has recently doubled the size of its laboratory facilities and hired new scientific and technical staff. According to AcryMed, the company has received inquiries that span a large number of medical device markets.
"The spread of hospital acquired infections is a significant problem that unnecessarily effect millions of U.S. patients each year and adds more than 28 billion dollars to our nation's healthcare costs," said Jack McMaken, president of AcryMed. "Since a large portion of harmful bacteria is harbored on medical devices such as indwelling catheters and implants, manufacturers are extremely interested in finding ways to curtail the role their products play in spreading infections. SilvaGard represents the first significant breakthrough in this area in quite some time."
SilvaGard prevents the spread of device-related infections by depositing antimicrobial silver nanoparticles onto the surfaces of medical devices and thus providing a protective barrier. Studies have shown that SilvaGard is not only safe for use, but also highly effective against a wide spectrum of infection-causing bacteria including MRSA and other antibiotic-resistant "superbugs."
The initial FDA market clearance of SilvaGard antimicrobial technology was given to I-Flow Corporation for marketing the company's ON-Q® SilverSoaker™ regional anesthesia delivery catheters. In recent findings presented at the Surgical Infection Society (SIS) meeting, I-Flow's ON-Q SilverSoaker antimicrobial catheter demonstrated a significantly lower risk of developing a surgical site infection in an on-going prospective study of patients undergoing colorectal surgery. The preliminary results captured the outcomes of 120 patients, randomized to either treatment with continuous local anesthetic using the antimicrobial treated ON-Q catheter or to the control treatment employing traditional pain relief. At 30-days post surgery, patients who received treatment with the antimicrobial ON-Q device had a significantly lower incidence of site infections at 0%, as compared to the control group at 22.9%. The study is scheduled to be complete by year-end. To learn more about the benefits of the ON-Q, visit www.AskYourSurgeon.com or www.IFLO.com.
Through collaborative development efforts, AcryMed and its medical device company partners expect to announce new product applications, leveraging SilvaGard-technology in the coming months.
####
About AcryMed
cryMed is a pioneering innovator at the forefront of innovations in the fields of infection control and wound healing. The company's SilvaSorb® products for advanced wound care and SilvaGard nanoparticle surface treatment for medical devices are among the breakthrough technologies that have distinguished AcryMed as an industry leader. AcryMed maintains on-site GMP manufacturing and lab facilities at its Portland, Oregon-based headquarters. The company is ISO certified and operates under ISO 13485 and EN 93/42/EEC. For more information on AcryMed, SilvaSorb, SilvaGard or other wound care and infection control technologies developed by AcryMed, visit their web site at http://www.acrymed.com or call 503-624-9830.
For more information, please click here
Contacts:
Kim Jacque
9560 SW Nimbus Ave.
Beaverton, Oregon 97008
Phone Number: 503.624.9830
Fax Number: 503.639.0846
kjacque@acrymed.com
Copyright © PRWeb™
DFG approves 11 new Collaborative Research Centers
News Release
5-Jun-2007
Changes to the program simplify the funding of independent junior research groups
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish eleven new Collaborative Research Centres (SFBs) on 1 July 2007. They will receive a total of 75.5 million euros in funding over the next four years. Research conducted in the centres will include work on the reconstruction of biological body functions using versatile “molecular switches” and innovative optical technology. Four of the new SFBs will be Transregional Collaborative Research Centres, which are located at multiple sites.
As well as establishing the newly approved Collaborative Research Centres, the committee also approved the continuation of 19 Collaborative Research Centres for another funding period, bringing the total number of Collaborative Research Centres financed by the DFG to 270 as of 1 July 2007. The total funding volume for 2007 will amount to approximately 388 million euros.
The committee also amended the funding programme: the “SFB independent junior research groups” component will become part of the Emmy Noether Programme, in order to bring more balance and simplicity to the funding offered by the DFG for young scientists and researchers who already hold a doctorate. In addition, as of 2008 the DFG will largely do away with the earmarking of certain funds that has existed up to now (for example funding specifically for inviting visiting researchers and scientists), in order to boost the individual responsibility of the Collaborative Research Centres and to simplify the utilisation of the funding granted to them. In the future, it will also be possible for Collaborative Research Centres to submit proposals for projects that will enable them to gather, generate, process and store the data relating to their projects in a more structured manner, using state-of-the-art computer data storage methods.
The new Collaborative Research Centres:
In Transregional Collaborative Research Centre 37 “Micro- and Nanosystems in Medicine – Reconstruction of Biologic Functions”, researchers from the fields of medicine, material science and the natural sciences will investigate the development of new technologies and methods of treatment in regenerative medicine using nano and laser technology. The centre will be based in Hannover, Aachen and Rostock. (Host university: Hannover Medical School (MHH), Coordinator: Axel Haverich)
Transregional Collaborative Research Centre 38 will deal with “Structures and Processes of the Initial Development of an Ecosystem in an Artificial Water Catchment Area”. Researchers from Cottbus, Munich and Zurich will work on the assumption that the early stages of an ecosystem have a decisive impact on its development and subsequent conditions. (Host university: Brandenburg Technical University, Cottbus, Coordinator: Reinhard F. Hüttl)
Transregional Collaborative Research Centre 45 will study the “Periods, Moduli Spaces and Arithmetic of Algebraic Varieties”. Researchers from the universities of Mainz, Bonn and Duisburg-Essen seek to combine various methodological approaches, ranging from the fields of algebraic and complex geometry to arithmetic geometry. (Host university: Johannes Gutenberg University, Mainz, Coordinator: Stefan Müller-Stach)
In Transregional Collaborative Research Centre 49 “Condensed Matter Systems with Variable Many-Body Interactions”, scientists and researchers from Frankfurt/Main, Kaiserslautern and Mainz will be investigating the collective behaviour of interacting many-body systems. This will serve to extend cooperation between quantum optics, solid state physics and chemistry. This centre will also include the first integrated Research Training Group, taking advantage of the recently introduced programme element designed to improve the qualification path for doctoral students participating in Collaborative Research Centres. (Host university: Johann Wolfgang Goethe University, Frankfurt am Main, Coordinator: Michael Lang)
Switchable molecules are able to change their properties reversibly in response to external stimulation, for example by light or magnetic field, a peculiarity that SFB 677 “Switch Functions” will investigate in greater depth. One of the objectives of their work will be to develop autonomous molecular switches suitable for use in medical or technical applications. (Host university: Christian Albrechts University, Kiel, Coordinator: Rainer Herges)
Researchers involved in SFB 728 “Environmental-Induced Aging Processes” will look at the mechanisms of aging at the molecular level and study their importance for the aging process of whole organs using models. In doing so, it may be possible to develop pharmacological prevention and treatment concepts. (Host university: Heinrich Heine University of Düsseldorf, Coordinator: Jean Krutmann)
The rejection of transplanted organs and the shortage of donated organs continue to pose challenges to transplantation medicine as a whole. This is the motivation for SFB 738 “Optimising Conventional and Innovative Transplantation”. (Host university: Hannover Medical School (MHH), Coordinator: Michael P. Manns)
The dynamic, i.e. temporally variable, parameters of molecules and biomolecules in chemical reactions are the topic that SFB 749 “Dynamic and Intermediate Molecular Transformations” will address. The structural analyses that are planned will be made possible by combining chemistry and biochemistry with theoretical chemistry and physics, as well as the application of state-of-the-art ultra-fast methods and high-precision theoretical procedures. (Host university: Ludwig-Maximilians University of Munich, Coordinator: Thomas Carell)
The SFB 755 “Nanoscale Photonic Imaging” plans to investigate complex systems such as macromolecular fluids and living cells. Innovative optical techniques, which allow exceptionally high spatial or temporal resolution to be achieved or which use X-rays, are being developed for this study. (Host university: Georg-August University of Göttingen, Coordinator: Tim Salditt)
Identifying a route to rapid and targeted development of a new class of structural materials is the overall objective of SFB 761 “Steel – ab initio. Designing Novel Ferric Materials Using Quantum Mechanics”. Researchers aim to do this using ab initio methods and other numerical processes, validated by experiment. (Host university: RWTH Technical University of Aachen, Coordinator: Wolfgang Bleck)
Researchers in SFB 766 “The Bacterial Cell Envelope: Structure, Function and Infection Interface” aim to develop molecular knowledge of the cell envelope of bacteria, which is currently limited, in order to be able to influence undesirable bacterial processes such as infections and the formation of biofilms, and potentially develop new antimicrobial agents. (Host university: Eberhard Karls University, Tübingen, Coordinator: Wolfgang Wohlleben)
Contact: Dr. Eva-Maria Streier
em.streier@dfg.de
49-228-885-2250
Deutsche Forschungsgemeinschaft
###
Further information is available from the coordinators of the respective Collaborative Research Centres.
At the DFG’s Head Office, please contact Klaus Wehrberger, Head, Research Centres Division, Tel. +49 (0)228 885-2355, e-mail: Klaus.Wehrberger@dfg.de.
Additional information on Collaborative Research Centres can be found at http://www.dfg.de/sfb/en.
5-Jun-2007
Changes to the program simplify the funding of independent junior research groups
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish eleven new Collaborative Research Centres (SFBs) on 1 July 2007. They will receive a total of 75.5 million euros in funding over the next four years. Research conducted in the centres will include work on the reconstruction of biological body functions using versatile “molecular switches” and innovative optical technology. Four of the new SFBs will be Transregional Collaborative Research Centres, which are located at multiple sites.
As well as establishing the newly approved Collaborative Research Centres, the committee also approved the continuation of 19 Collaborative Research Centres for another funding period, bringing the total number of Collaborative Research Centres financed by the DFG to 270 as of 1 July 2007. The total funding volume for 2007 will amount to approximately 388 million euros.
The committee also amended the funding programme: the “SFB independent junior research groups” component will become part of the Emmy Noether Programme, in order to bring more balance and simplicity to the funding offered by the DFG for young scientists and researchers who already hold a doctorate. In addition, as of 2008 the DFG will largely do away with the earmarking of certain funds that has existed up to now (for example funding specifically for inviting visiting researchers and scientists), in order to boost the individual responsibility of the Collaborative Research Centres and to simplify the utilisation of the funding granted to them. In the future, it will also be possible for Collaborative Research Centres to submit proposals for projects that will enable them to gather, generate, process and store the data relating to their projects in a more structured manner, using state-of-the-art computer data storage methods.
The new Collaborative Research Centres:
In Transregional Collaborative Research Centre 37 “Micro- and Nanosystems in Medicine – Reconstruction of Biologic Functions”, researchers from the fields of medicine, material science and the natural sciences will investigate the development of new technologies and methods of treatment in regenerative medicine using nano and laser technology. The centre will be based in Hannover, Aachen and Rostock. (Host university: Hannover Medical School (MHH), Coordinator: Axel Haverich)
Transregional Collaborative Research Centre 38 will deal with “Structures and Processes of the Initial Development of an Ecosystem in an Artificial Water Catchment Area”. Researchers from Cottbus, Munich and Zurich will work on the assumption that the early stages of an ecosystem have a decisive impact on its development and subsequent conditions. (Host university: Brandenburg Technical University, Cottbus, Coordinator: Reinhard F. Hüttl)
Transregional Collaborative Research Centre 45 will study the “Periods, Moduli Spaces and Arithmetic of Algebraic Varieties”. Researchers from the universities of Mainz, Bonn and Duisburg-Essen seek to combine various methodological approaches, ranging from the fields of algebraic and complex geometry to arithmetic geometry. (Host university: Johannes Gutenberg University, Mainz, Coordinator: Stefan Müller-Stach)
In Transregional Collaborative Research Centre 49 “Condensed Matter Systems with Variable Many-Body Interactions”, scientists and researchers from Frankfurt/Main, Kaiserslautern and Mainz will be investigating the collective behaviour of interacting many-body systems. This will serve to extend cooperation between quantum optics, solid state physics and chemistry. This centre will also include the first integrated Research Training Group, taking advantage of the recently introduced programme element designed to improve the qualification path for doctoral students participating in Collaborative Research Centres. (Host university: Johann Wolfgang Goethe University, Frankfurt am Main, Coordinator: Michael Lang)
Switchable molecules are able to change their properties reversibly in response to external stimulation, for example by light or magnetic field, a peculiarity that SFB 677 “Switch Functions” will investigate in greater depth. One of the objectives of their work will be to develop autonomous molecular switches suitable for use in medical or technical applications. (Host university: Christian Albrechts University, Kiel, Coordinator: Rainer Herges)
Researchers involved in SFB 728 “Environmental-Induced Aging Processes” will look at the mechanisms of aging at the molecular level and study their importance for the aging process of whole organs using models. In doing so, it may be possible to develop pharmacological prevention and treatment concepts. (Host university: Heinrich Heine University of Düsseldorf, Coordinator: Jean Krutmann)
The rejection of transplanted organs and the shortage of donated organs continue to pose challenges to transplantation medicine as a whole. This is the motivation for SFB 738 “Optimising Conventional and Innovative Transplantation”. (Host university: Hannover Medical School (MHH), Coordinator: Michael P. Manns)
The dynamic, i.e. temporally variable, parameters of molecules and biomolecules in chemical reactions are the topic that SFB 749 “Dynamic and Intermediate Molecular Transformations” will address. The structural analyses that are planned will be made possible by combining chemistry and biochemistry with theoretical chemistry and physics, as well as the application of state-of-the-art ultra-fast methods and high-precision theoretical procedures. (Host university: Ludwig-Maximilians University of Munich, Coordinator: Thomas Carell)
The SFB 755 “Nanoscale Photonic Imaging” plans to investigate complex systems such as macromolecular fluids and living cells. Innovative optical techniques, which allow exceptionally high spatial or temporal resolution to be achieved or which use X-rays, are being developed for this study. (Host university: Georg-August University of Göttingen, Coordinator: Tim Salditt)
Identifying a route to rapid and targeted development of a new class of structural materials is the overall objective of SFB 761 “Steel – ab initio. Designing Novel Ferric Materials Using Quantum Mechanics”. Researchers aim to do this using ab initio methods and other numerical processes, validated by experiment. (Host university: RWTH Technical University of Aachen, Coordinator: Wolfgang Bleck)
Researchers in SFB 766 “The Bacterial Cell Envelope: Structure, Function and Infection Interface” aim to develop molecular knowledge of the cell envelope of bacteria, which is currently limited, in order to be able to influence undesirable bacterial processes such as infections and the formation of biofilms, and potentially develop new antimicrobial agents. (Host university: Eberhard Karls University, Tübingen, Coordinator: Wolfgang Wohlleben)
Contact: Dr. Eva-Maria Streier
em.streier@dfg.de
49-228-885-2250
Deutsche Forschungsgemeinschaft
###
Further information is available from the coordinators of the respective Collaborative Research Centres.
At the DFG’s Head Office, please contact Klaus Wehrberger, Head, Research Centres Division, Tel. +49 (0)228 885-2355, e-mail: Klaus.Wehrberger@dfg.de.
Additional information on Collaborative Research Centres can be found at http://www.dfg.de/sfb/en.
Wednesday, May 30, 2007
Microban International Partners With Rubbermaid to Introduce First Commercial High Chair With Built-in Microban(R) Antimicrobial Protection
News Release
HUNTERSVILLE, N.C., May 29 /PRNewswire/ -- Microban International, Ltd., the global leader in built-in antimicrobial technology, has extended their existing partnership with Rubbermaid Consumer Products to Rubbermaid Commercial Products, the market leader in safety and productivity solutions for the foodservice industry.
Rubbermaid Commercial Products launched its new Sturdy Chair(TM) Youth Seat with Microban(R) antimicrobial product protection at the National Restaurant Association Show, May 19-22, in Chicago, IL. This innovative high chair is the first product introduction resulting from the exclusive alliance, and is the only high chair product available to the foodservice industry with Microban(R) antimicrobial protection. Microban technology works continuously to help prevent the growth of bacteria that can cause stains and odors, giving new peace of mind to food service operators and their patrons.
Under the right conditions, such as those commonly found on untreated high chairs, bacteria can double in number every 20 minutes. With the added protection of Microban(R) antimicrobial technology, the Sturdy Chair(TM) Youth Seat will stay cleaner between cleanings, making this a smart investment for food service operators.
"We are very excited about the addition of Microban(R) antimicrobial protection to Rubbermaid high chairs," said David J. Meyers, CEO of Microban International, Ltd. "As the foodservice industry continues to respond to pressure from consumers for a cleaner dining environment, products with Microban(R) technology will help fill this need by keeping foodservice products cleaner for longer. "
Rubbermaid Commercial's Product Director, Virginia Murray, noted, "We are especially excited as this exclusive partnership is groundbreaking within the commercial foodservice industry, and we are hopeful that it will lead to new opportunities for both companies."
About Microban International
Microban International, Ltd. is a global technology and marketing company dedicated to enhancing high quality consumer, industrial and medical products with branded built-in protection from microbes. Microban International licenses the Microban(R) global brand name, sells custom-engineered compounds, and provides a range of services, including regulatory and marketing support. The Microban(R) brand promises continuous and durable antimicrobial product protection, built-in during manufacture to not wear out for the useful life of the product. Microban International is headquartered in North Carolina with operations in North America, Europe and Asia. For more information, please contact (704) 875-0806 or visit http://www.microban.com/ . About Rubbermaid Commercial Products
Rubbermaid Commercial Products, headquartered in Winchester, VA, is an ISO 9001 manufacturer of innovative, solution-based products for commercial and institutional markets worldwide. Since 1968, RCP has pioneered technologies and system solutions in the categories of food service, sanitary maintenance, waste handling, material transport and safety products. Rubbermaid Commercial Products is a business unit of Newell Rubbermaid Inc., a global marketer of consumer and commercial products with annual sales of approximately $6 billion. For more information, please visit Rubbermaid Commercial Product's web site at http://www.rcpworksmarter.com/ . CONTACT: Sarah Hoxie
(704) 766-1068
Microban International, Ltd.
CONTACT: Sarah Hoxie for Microban International, Ltd., +1-704-766-1068Web site: http://www.microban.com/ http://www.rcpworksmarter.com/
HUNTERSVILLE, N.C., May 29 /PRNewswire/ -- Microban International, Ltd., the global leader in built-in antimicrobial technology, has extended their existing partnership with Rubbermaid Consumer Products to Rubbermaid Commercial Products, the market leader in safety and productivity solutions for the foodservice industry.
Rubbermaid Commercial Products launched its new Sturdy Chair(TM) Youth Seat with Microban(R) antimicrobial product protection at the National Restaurant Association Show, May 19-22, in Chicago, IL. This innovative high chair is the first product introduction resulting from the exclusive alliance, and is the only high chair product available to the foodservice industry with Microban(R) antimicrobial protection. Microban technology works continuously to help prevent the growth of bacteria that can cause stains and odors, giving new peace of mind to food service operators and their patrons.
Under the right conditions, such as those commonly found on untreated high chairs, bacteria can double in number every 20 minutes. With the added protection of Microban(R) antimicrobial technology, the Sturdy Chair(TM) Youth Seat will stay cleaner between cleanings, making this a smart investment for food service operators.
"We are very excited about the addition of Microban(R) antimicrobial protection to Rubbermaid high chairs," said David J. Meyers, CEO of Microban International, Ltd. "As the foodservice industry continues to respond to pressure from consumers for a cleaner dining environment, products with Microban(R) technology will help fill this need by keeping foodservice products cleaner for longer. "
Rubbermaid Commercial's Product Director, Virginia Murray, noted, "We are especially excited as this exclusive partnership is groundbreaking within the commercial foodservice industry, and we are hopeful that it will lead to new opportunities for both companies."
About Microban International
Microban International, Ltd. is a global technology and marketing company dedicated to enhancing high quality consumer, industrial and medical products with branded built-in protection from microbes. Microban International licenses the Microban(R) global brand name, sells custom-engineered compounds, and provides a range of services, including regulatory and marketing support. The Microban(R) brand promises continuous and durable antimicrobial product protection, built-in during manufacture to not wear out for the useful life of the product. Microban International is headquartered in North Carolina with operations in North America, Europe and Asia. For more information, please contact (704) 875-0806 or visit http://www.microban.com/ . About Rubbermaid Commercial Products
Rubbermaid Commercial Products, headquartered in Winchester, VA, is an ISO 9001 manufacturer of innovative, solution-based products for commercial and institutional markets worldwide. Since 1968, RCP has pioneered technologies and system solutions in the categories of food service, sanitary maintenance, waste handling, material transport and safety products. Rubbermaid Commercial Products is a business unit of Newell Rubbermaid Inc., a global marketer of consumer and commercial products with annual sales of approximately $6 billion. For more information, please visit Rubbermaid Commercial Product's web site at http://www.rcpworksmarter.com/ . CONTACT: Sarah Hoxie
(704) 766-1068
Microban International, Ltd.
CONTACT: Sarah Hoxie for Microban International, Ltd., +1-704-766-1068Web site: http://www.microban.com/ http://www.rcpworksmarter.com/
Subscribe to:
Posts (Atom)
